- Home
- PHR
PHR
Phreesia Inc.
as 07-26-2024 4:00pm EST
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 1.3B | IPO Year: | 2019 |
| Target Price: | $30.54 | AVG Volume (30 days): | 462.1K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.05 - $32.11 | Next Earning Date: | 09-04-2024 |
| Revenue: | $373,671,000 | Revenue Growth: | 23.98% |
| Revenue Growth (this year): | 19.21% | Revenue Growth (next year): | 18.24% |
Stock Insider Trading Activity of Phreesia Inc. (PHR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roberts Evan | PHR | Chief Operating Officer | Jul 16 '24 | Sell | $23.74 | 1,669 | $39,614.72 | 753,234 | SEC Form 4 |
| Gandhi Balaji | PHR | Chief Financial Officer | Jul 16 '24 | Sell | $23.74 | 783 | $18,584.97 | 96,447 | SEC Form 4 |
| Indig Chaim | PHR | Chief Executive Officer | Jul 16 '24 | Sell | $23.74 | 2,644 | $62,756.93 | 1,219,361 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Jul 16 '24 | Sell | $23.74 | 1,820 | $43,198.79 | 202,218 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Jun 21 '24 | Sell | $20.24 | 27 | $546.39 | 6,953 | SEC Form 4 |
| Gunzburg Janet | PHR | Principal Accounting Officer | Jun 21 '24 | Sell | $20.24 | 114 | $2,306.96 | 34,820 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Jun 18 '24 | Sell | $19.73 | 66 | $1,302.33 | 6,980 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Jun 18 '24 | Sell | $19.20 | 41 | $787.08 | 7,046 | SEC Form 4 |
| Gunzburg Janet | PHR | Principal Accounting Officer | May 1 '24 | Sell | $21.00 | 286 | $6,005.63 | 34,934 | SEC Form 4 |
| Gunzburg Janet | PHR | Principal Accounting Officer | Apr 18 '24 | Sell | $22.85 | 912 | $20,836.46 | 35,220 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Apr 18 '24 | Sell | $22.85 | 269 | $6,145.84 | 7,087 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Apr 15 '24 | Sell | $22.86 | 2,212 | $50,560.57 | 204,038 | SEC Form 4 |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Apr 15 '24 | Sell | $22.86 | 685 | $15,657.32 | 119,010 | SEC Form 4 |
| Roberts Evan | PHR | Chief Operating Officer | Apr 15 '24 | Sell | $22.86 | 2,029 | $46,377.66 | 754,903 | SEC Form 4 |
| Hoffman Allison C | PHR | General Counsel & Secretary | Apr 15 '24 | Sell | $22.86 | 1,238 | $28,297.46 | 135,621 | SEC Form 4 |
| Gandhi Balaji | PHR | Chief Financial Officer | Apr 15 '24 | Sell | $22.86 | 948 | $21,668.82 | 97,230 | SEC Form 4 |
| Indig Chaim | PHR | Chief Executive Officer | Apr 15 '24 | Sell | $22.86 | 3,392 | $77,532.30 | 1,222,005 | SEC Form 4 |
| Gunzburg Janet | PHR | Principal Accounting Officer | Apr 10 '24 | Sell | $23.10 | 2,768 | $63,928.07 | 36,132 | SEC Form 4 |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Apr 8 '24 | Sell | $22.62 | 3,320 | $75,085.45 | 123,497 | SEC Form 4 |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Apr 8 '24 | Sell | $23.02 | 34 | $782.55 | 123,463 | SEC Form 4 |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Apr 8 '24 | Sell | $23.43 | 3,768 | $88,276.70 | 119,695 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Apr 8 '24 | Sell | $22.62 | 3,875 | $87,637.39 | 206,289 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Apr 8 '24 | Sell | $23.02 | 39 | $897.64 | 206,250 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Apr 8 '24 | Sell | $22.62 | 245 | $5,540.94 | 7,358 | SEC Form 4 |
| Linetsky David | PHR | SVP, Life Sciences | Apr 8 '24 | Sell | $23.02 | 2 | $46.03 | 7,356 | SEC Form 4 |
Latest Phreesia Inc. News
PHR Breaking Stock News: Dive into PHR Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Wall Street Analysts Think Phreesia (PHR) Could Surge 27.77%: Read This Before Placing a Bet
Zacks
14 days ago
Phreesia (PHR) Upgraded to Strong Buy: Here's What You Should Know
Simply Wall St.
14 days ago
Phreesia (NYSE:PHR) investors are sitting on a loss of 67% if they invested three years ago
MT Newswires
15 days ago
KeyBanc Adjusts Price Target on Phreesia to $25 From $27, Maintains Overweight Rating
Zacks
a month ago
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Zacks
a month ago
5 Medical Info Systems Stock to Buy for a Stable Portfolio
Business Wire
2 months ago
New Research Illustrates How to Drive Earlier Diagnosis and Treatment of Kidney Disease
Motley Fool
2 months ago
Where Will CrowdStrike Stock Be in 1 Year?
Compare PHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHR Phreesia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.